Knowledge Is Not Enough For Enforcement In FDA’s Final Research-Use Dx Guidance
This article was originally published in The Gray Sheet
Executive Summary
Companies are at risk of enforcement if they take direct steps to encourage use of their research-use or investigational-use only tests for clinical diagnostic indications, according to the guidance. But, in response to public comments, FDA removed references that a company knowing or having “reason to know” that a lab is inappropriately using a test is grounds for enforcement.